{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:15:51Z","timestamp":1761488151454},"reference-count":26,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2009,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>High fatality rates and multiple cases of transmission of avian H5N1 influenza viruses to humans illustrate the urgent need for an efficacious, cross-protective vaccine against H5N1 strains. Extensive genetic characterization of H5N1 strains has elucidated the natural evolutionary relationship of these strains, linking groups known as clades to a common ancestor. Although the clades and subclades probably differ sufficiently in their antigenic structure to warrant the preparation of different vaccines, there is some evidence that cross-reactive immunity can be afforded. We aimed to assess the immunogenicity of a clade 1 H5N1 (NIBRG-14) whole-virus vaccine with an aluminum phosphate adjuvant and to determine whether it can induce cross-reactive immunity against antigenically drifted clade 2 H5N1 strains, both those derived by reverse genetics and wild-type isolates. A total of 88 (44 adult and 44 elderly) subjects, who received one dose (6 \u03bcg) of the vaccine, were studied. As judged by U.S. and European licensing criteria based on hemagglutination inhibition, the subjects developed cross-reactive immunity against all studied H5N1 strains belonging to a clade different from that of the strain utilized to produce the vaccine. Our findings highlight the importance of stockpiling, since cross-immune reactions induced by prepandemic vaccines will likely reduce morbidity and mortality in case of a pandemic.<\/jats:p>","DOI":"10.1128\/cvi.00327-08","type":"journal-article","created":{"date-parts":[[2008,11,20]],"date-time":"2008-11-20T01:44:24Z","timestamp":1227145464000},"page":"437-443","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":18,"title":["Cross-Reactive Immunity to Clade 2 Strains of Influenza Virus A Subtype H5N1 Induced in Adults and Elderly Patients by Fluval, a Prototype Pandemic Influenza Virus Vaccine Derived by Reverse Genetics, Formulated with a Phosphate Adjuvant, and Directed to Clade 1 Strains"],"prefix":"10.1128","volume":"16","author":[{"given":"Gyo\u0308rgy","family":"Fazekas","sequence":"first","affiliation":[{"name":"Omninvest Ltd., Pilisborosjeno"},{"name":"National Institute of Epidemiology"},{"name":"State Health Center, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Martosne-Mendi","sequence":"additional","affiliation":[{"name":"Omninvest Ltd., Pilisborosjeno"},{"name":"National Institute of Epidemiology"},{"name":"State Health Center, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Istvan","family":"Jankovics","sequence":"additional","affiliation":[{"name":"Omninvest Ltd., Pilisborosjeno"},{"name":"National Institute of Epidemiology"},{"name":"State Health Center, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Istvan","family":"Szilvasy","sequence":"additional","affiliation":[{"name":"Omninvest Ltd., Pilisborosjeno"},{"name":"National Institute of Epidemiology"},{"name":"State Health Center, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoltan","family":"Vajo","sequence":"additional","affiliation":[{"name":"Omninvest Ltd., Pilisborosjeno"},{"name":"National Institute of Epidemiology"},{"name":"State Health Center, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.1016\/j.vaccine.2007.07.027","volume":"25","year":"2007","unstructured":"Carrat, F., and A. Flahault. 2007. Influenza vaccine: the challenge of antigenic drift. Vaccine25:6852-6862.","journal-title":"Vaccine"},{"key":"e_1_3_1_3_2","unstructured":"Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application. 2004"},{"key":"e_1_3_1_4_2","unstructured":"Note for guidance on harmonisation of requirements for influenza vaccines. 1997"},{"key":"e_1_3_1_5_2","unstructured":"Expert advisory groups on human H5N1 vaccines. 2007"},{"key":"e_1_3_1_6_2","first-page":"3406","year":"2007","unstructured":"European Directorate for the Quality of Medicines & HealthCare. July 2007. European pharmacopeia, 5th ed., supplement 5.8, p. 3406-3407. CD-ROM. European Directorate for the Quality of Medicines & HealthCare, Strasbourg, France.","journal-title":"European pharmacopeia"},{"key":"e_1_3_1_7_2","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nature04795","volume":"442","year":"2006","unstructured":"Ferguson, N. M., D. A. Cummings, C. Fraser, J. C. Cajka, P. C. Cooley, and D. S. Burke. 2006. Strategies for mitigating an influenza pandemic. Nature442:448-452.","journal-title":"Nature"},{"key":"e_1_3_1_8_2","doi-asserted-by":"crossref","first-page":"5935","DOI":"10.1073\/pnas.0601266103","volume":"103","year":"2006","unstructured":"Germann, T. C., K. Kadau, I. M. Longini, Jr., and C. A. Macken. 2006. Mitigation strategies for pandemic influenza in the United States. Proc. Natl. Acad. Sci. USA103:5935-5940.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"e_1_3_1_9_2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3201\/eid1401.061283","volume":"14","year":"2008","unstructured":"Gioia, C., C. Castilletti, M. Tempestilli, P. Piacentini, L. Bordi, R. Chiappini, C. Agrati, S. Squarcione, G. Ippolito, V. Puro, M. R. Capobianchi, and F. Poccia. 2008. Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. Emerg. Infect. Dis.14:121-128.","journal-title":"Emerg. Infect. Dis."},{"key":"e_1_3_1_10_2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/505225","volume":"194","year":"2006","unstructured":"Govorkova, E. A., R. J. Webby, J. Humberd, J. P. Seiler, and R. G. Webster. 2006. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J. Infect. Dis.194:159-167.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_1_11_2","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1086\/521304","volume":"196","year":"2007","unstructured":"Ichinohe, T., S. Tamura, A. Kawaguchi, A. Ninomiya, M. Imai, S. Itamura, T. Odagiri, M. Tashiro, H. Takahashi, H. Sawa, W. M. Mitchell, D. R. Strayer, W. A. Carter, J. Chiba, T. Kurata, T. Sata, and H. Hasegawa. 2007. Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J. Infect. Dis.196:1313-1320.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_1_12_2","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1056\/NEJMoa060930","volume":"355","year":"2006","unstructured":"Kandun, I. N., H. Wibisono, E. R. Sedyaningsih, Yusharmen, W. Hadisoedarsuno, W. Purba, H. Santoso, C. Septiawati, E. Tresnaningsih, B. Heriyanto, D. Yuwono, S. Harun, S. Soeroso, S. Giriputra, P. J. Blair, A. Jeremijenko, H. Kosasih, S. D. Putnam, G. Samaan, M. Silitonga, K. H. Chan, L. L. Poon, W. Lim, A. Klimov, S. Lindstrom, Y. Guan, R. Donis, J. Katz, N. Cox, M. Peiris, and T. M. Uyeki. 2006. Three Indonesian clusters of H5N1 virus infection in 2005. N. Engl. J. Med.355:2186-2194.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_1_13_2","unstructured":"Concepts and procedures for laboratory based influenza surveillance. 1982"},{"key":"e_1_3_1_14_2","first-page":"1","year":"2003","unstructured":"Klimov, A., and N. Cox. 2003. Serologic diagnosis of influenza virus infections by hemagglutination inhibition chapter 7, p. 1-5. In Influenza laboratory course. Centers for Disease Control and Prevention, Atlanta, GA.","journal-title":"In Influenza laboratory course."},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61297-5"},{"key":"e_1_3_1_16_2","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1016\/j.vaccine.2006.05.039","volume":"24","year":"2006","unstructured":"Lu, X., L. E. Edwards, J. A. Desheva, D. C. Nguyen, A. Rekstin, I. Stephenson, K. Szretter, N. J. Cox, L. G. Rudenko, A. Klimov, and J. M. Katz. 2006. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses. Vaccine24:6588-6593.","journal-title":"Vaccine"},{"key":"e_1_3_1_17_2","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1016\/j.vaccine.2007.01.083","volume":"25","year":"2007","unstructured":"Ninomiya, A., M. Imai, M. Tashiro, and T. Odagiri. 2007. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine25:3554-3560.","journal-title":"Vaccine"},{"key":"e_1_3_1_18_2","first-page":"493","volume":"27","year":"1938","unstructured":"Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty per cent endpoints. Am. J. Hyg.27:493-497.","journal-title":"Am. J. Hyg."},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.37.4.937-943.1999"},{"key":"e_1_3_1_20_2","first-page":"185","volume":"3","year":"1952","unstructured":"Takatsy, G. 1952. Purified precipitated virus obtained by a new simple method. Acta Med. Acad. Sci. Hung.3:185-191.","journal-title":"Acta Med. Acad. Sci. Hung."},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.11.5141-5150.2001"},{"key":"e_1_3_1_22_2","unstructured":"U.S. Food and Drug Administration. May 2007. Guidance for industry. Clinical data needed to support the licensure of pandemic influenza vaccines. http:\/\/www.fda.gov\/cber\/gdlns\/panfluvac.htm\n."},{"key":"e_1_3_1_23_2","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3201\/eid1305.061248","volume":"13","year":"2007","unstructured":"Vajo, Z., L. Kosa, I. Visontay, M. Jankovics, and I. Jankovics. 2007. Inactivated whole virus influenza A (H5N1) vaccine. Emerg. Infect. Dis.13:807-808. (Letter.)","journal-title":"Emerg. Infect. Dis."},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.23.2.240-245.1986"},{"key":"e_1_3_1_25_2","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1056\/NEJMp068205","volume":"355","year":"2006","unstructured":"Webster, R. G., and E. A. Govorkova. 2006. H5N1 influenza\u2014continuing evolution and spread. N. Engl. J. Med.355:2174-2177.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_1_26_2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0092-1157(77)80008-5","volume":"5","year":"1977","unstructured":"Wood, J. M., G. C. Schild, R. W. Newman, and V. Seagroatt. 1977. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J. Biol. Stand.5:237-247.","journal-title":"J. Biol. Stand."},{"key":"e_1_3_1_27_2","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.3201\/eid1110.050644","volume":"11","year":"2005","unstructured":"World Health Organization Global Influenza Program Surveillance Network. 2005. Evolution of H5N1 avian influenza viruses in Asia. Emerg. Infect. Dis.11:1515-1521.","journal-title":"Emerg. Infect. Dis."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00327-08","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00327-08","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T15:55:11Z","timestamp":1627574111000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00327-08"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["10.1128\/CVI.00327-08"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00327-08","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4]]},"assertion":[{"value":"2008-09-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-11-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}